<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">29655448</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1557-9875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurologic clinics</Title>
          <ISOAbbreviation>Neurol Clin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology.</ArticleTitle>
        <Pagination>
          <StartPage>253</StartPage>
          <EndPage>260</EndPage>
          <MedlinePgn>253-260</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ncl.2018.01.002</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0733-8619(18)30002-1</ELocationID>
        <Abstract>
          <AbstractText>Myasthenia gravis (MG) is a rare disease, but the most common disorder of the neuromuscular junction. It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles. The majority of patients with MG first present with ocular symptoms. Most patients with MG will experience at least 1 exacerbation of symptoms throughout the course of their illness. This article will cover the epidemiology, clinical presentation, classification, and natural history of MG.</AbstractText>
          <CopyrightInformation>Copyright Â© 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hehir</LastName>
            <ForeName>Michael K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Larner College of Medicine at the University of Vermont, University of Vermont, 1 South Prospect Street, Burlington, VT 05401, USA. Electronic address: Michael.hehir@uvmhealth.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silvestri</LastName>
            <ForeName>Nicholas J</ForeName>
            <Initials>NJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University at Buffalo Jacobs School of Medicine &amp; Biomedical Sciences, 1010 Main Street, Buffalo, New York 14202, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurol Clin</MedlineTA>
        <NlmUniqueID>8219232</NlmUniqueID>
        <ISSNLinking>0733-8619</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Acetylcholine receptor</Keyword>
        <Keyword MajorTopicYN="Y">Antimuscle-specific kinase</Keyword>
        <Keyword MajorTopicYN="Y">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="Y">Occular</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29655448</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ncl.2018.01.002</ArticleId>
        <ArticleId IdType="pii">S0733-8619(18)30002-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
